Amgen Enbrel Focus Includes Push For Earlier Treatment Of RA Patients
Executive Summary
Amgen's marketing strategy for Enbrel (etanercept) includes closing the gap between diagnosis and initiation of therapy in patients with moderate rheumatoid arthritis
You may also be interested in...
Wyeth/Amgen Enbrel Adds 25,000 Patients In Q1; Prevnar Back Orders Cleared
Improved supply for Wyeth/Amgen's Enbrel is allowing for the first significant increase in the number of patients on the TNF inhibitor in more than a year
Wyeth/Amgen Enbrel Adds 25,000 Patients In Q1; Prevnar Back Orders Cleared
Improved supply for Wyeth/Amgen's Enbrel is allowing for the first significant increase in the number of patients on the TNF inhibitor in more than a year
TNF inhibitor safety
Safety of tumor necrosis factor inhibitors and a possible link to lymphoma will be discussed by FDA's Arthritis Drugs Advisory Committee March 4. The committee will receive safety updates on all three marketed TNF inhibitors - Amgen's Enbrel, Centocor's Remicade and Abbott's Humira. The committee's TNF inhibitor safety review in August 2001 focused on the risk of immune disorders (1"The Pink Sheet" Aug. 20, 2001, p. 7)...